UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Cell reports (Cambridge), 2014-01, Vol.6 (2), p.377-387

2014

Volltextzugriff (PDF)

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (13), p.3690-3701

2016

Volltextzugriff (PDF)

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

PloS one, 2014-12, Vol.9 (12), p.e115383-e115383

2014

Volltextzugriff (PDF)

Lung Cancer in the Older Patient

Clinics in geriatric medicine, 2017-11, Vol.33 (4), p.563-577

2017

Volltextzugriff (PDF)

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

Clinical cancer research, 2014-12, Vol.20 (24), p.6336-6345

2014

Volltextzugriff (PDF)

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Molecular cancer therapeutics, 2016-06, Vol.15 (6), p.1397-1404

2016

Volltextzugriff (PDF)

S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

Oncogene, 2020-12, Vol.39 (49), p.7181-7195

2020

Volltextzugriff (PDF)

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early‐phase oncology clinical trials

Cancer, 2016-11, Vol.122 (21), p.3401-3409

2016

Volltextzugriff (PDF)

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

Journal of clinical oncology, 2010-02, Vol.28 (4), p.614-619

2010

Volltextzugriff (PDF)

Fingerprinting the circulating repertoire of antibodies from cancer patients

Nature biotechnology, 2003-01, Vol.21 (1), p.57-63

2003

Volltextzugriff (PDF)

Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers

Cancer, 2021-02, Vol.127 (3), p.391-402

2021

Volltextzugriff (PDF)

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Oncotarget, 2015-05, Vol.6 (14), p.12809-12821

2015

Volltextzugriff (PDF)

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

Frontiers in oncology, 2020-12, Vol.10, p.566315-566315

2020

Volltextzugriff (PDF)

Designing Survey-Based Mobile Interfaces for Rural Patients With Cancer Using Apple's ResearchKit and CareKit: Usability Study

JMIR formative research, 2024-09, Vol.8, p.e57801

2024

Volltextzugriff (PDF)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Oncotarget, 2016-10, Vol.7 (41), p.67521-67531

2016

Volltextzugriff (PDF)

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

PloS one, 2014-02, Vol.9 (2), p.e89388-e89388

2014

Volltextzugriff (PDF)

Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky

Clinical lung cancer, 2021-11, Vol.22 (6), p.e911-e920

2021

Volltextzugriff (PDF)

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents

Molecular cancer therapeutics, 2014-12, Vol.13 (12), p.3175-3184

2014

Volltextzugriff (PDF)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

Oncotarget, 2014-11, Vol.5 (22), p.11168-11179

2014

Volltextzugriff (PDF)

Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes

Journal of the Royal Statistical Society Series C: Applied Statistics, 2017-01, Vol.66 (1), p.201-224

2017

Volltextzugriff (PDF)

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care

Clinical lung cancer, 2018-11, Vol.19 (6), p.e823-e830

2018

Volltextzugriff (PDF)

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9051-9051

2020

Volltextzugriff (PDF)

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

Oncotarget, 2015-09, Vol.6 (29), p.26886-26894

2015

Volltextzugriff (PDF)

1 – 25 von 202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(181)
Mit Volltextzugriff
(196)

Publikationsform

Artikel
(201)
Berichte
(1)

Sprache

Englisch
(201)
Deutsch
(1)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(84)
Humans
(81)
Oncology
(78)
Female
(62)
Middle Aged
(60)
Male
(59)
Aged
(58)
Adult
(57)
Aged, 80 And Over
(34)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(32)
Treatment Outcome
(29)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(26)
Lung Neoplasms - Drug Therapy
(26)
Chemotherapy
(23)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(18)
Biological And Medical Sciences
(18)
Lung Cancer
(18)
Mutation
(18)
Neoplasms - Drug Therapy
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Lung Cancer in the Older Patient

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early‐phase oncology clinical trials

Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

Fingerprinting the circulating repertoire of antibodies from cancer patients

Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect

Designing Survey-Based Mobile Interfaces for Rural Patients With Cancer Using Apple's ResearchKit and CareKit: Usability Study

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors

Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

Parametric dose standardization for optimizing two-agent combinations in a phase I-II trial with ordinal outcomes

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non–Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care

Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF‐mutated melanoma and other advanced malignancies

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

Suchergebnisse filtern